Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 7/20 | 0.51 |
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744555 | 1.00 | PPARA (0.54) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL19661441 | 0.93 | CTSK (0.54) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL834063 | 0.88 | PPARA (0.54) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL834064 | 0.88 | PPARA (0.54) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL836148 | 0.86 | CTSK (0.55) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL2108529 | 0.86 | CTSS (0.65) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL836149 | 0.86 | CTSK (0.55) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL26334491 | 0.85 | PPARA (0.51) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL3635267 | 0.85 | PPARA (0.51) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL13044357 | 0.83 | PPARA (0.53) | PPARAPPARGPPARDCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829304-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829304-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829304-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-03 | — | — | US | disclosed |
| WO-2005042481-A2 | COMPOUNDS AND RELATED METHODS FOR MUTANT p53 REACTIVATION | NORTHWESTERN UNIVERSITY (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | TP53, TP53BP1, MDM2 | PPARA 1324/4885PPARG 687/4885PPARD 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.